In two months, Covid-19 can easily export curbs: Adar Poonawalla

The export restrictions for Covid vaccines are expected to be alleviated within a two-month period by Adar Poonawalla, Chief Executive Officer of the Serum Institute of India (SII), provided India has created a enough stock to cope with the third wave.

The provision of raw materials for Novavax vaccines has improved compared to March and in December, Poonawalla told the media, SII plans to announce its monthly manufacturing plan.

“No export ban was in place, but temporary restrictions were in place and rightly so. In the next month or two I think these will be slowly easy, but I don’t want to go astray. But soon,” he said, adding that India is close to a point in which more than enough stocks of vaccines exist.

The government of India, Poonawalla says, is relieving the export restrictions, and it will follow what the Center thinks is appropriate.

“The Centre has to balance the needs of the country and stockpile vaccines for India in case of the third and fourth waves. Taking lessons from the first and second waves, the government is rightly being very cautious,” he said.

SII is expanding its Covishield capacity, which now stands at around 160 million doses a month. From October, it is expected to touch 200 million doses a month.

On the other hand, the production of the Novavax vaccine is not constrained by SII’s capacities, but by raw materials, Poonawalla said. SII is working on developing alternative vendor sources for critical raw materials. “Developing new supplies takes time. The silver lining is we have got people who can make quality raw materials, but they are inundated with orders from different vaccine companies – from Korea, China, Europe, etc,” he added.

SII is trying its best to scale up the production of the Novavax vaccine, Poonawalla said, and that there have been major improvements in raw material supplies since March. “We will wait and see, and in December, for sure, we can comment on what our monthly production will be,” he said.

As for the Novavax vaccine’s clinical trials on paediatric population, Poonawalla said the company has started trials, and three to four months is the minimum timeframe for that. By January-February, there is a possibility that Covovax (SII-manufactured Novavax vaccine) could be ready for approval for use in kids.

 

Medically Speaking

Recent Posts

Harness the Power of Rice Water

Rice water, rich in inositol, antioxidants, vitamins, and minerals, protects hair from sunlight damage and…

5 hours ago

“8 Powerful Herbs and Supplements to Beat Bloating and Boost Your Gut Health Naturally”

Natural Remedies for Bloating: 8 Herbs and Supplements That Work Wonders for Your Gut Health…

5 hours ago

“Unlock the Power of Oil Pulling: Discover How This Simple Practice Improves Oral Health and Freshens Your Breath”

Benefits of Oil Pulling: Stops Bad Breath, Keeps Gums Healthy, But Can't Replace Brushing Oil…

5 hours ago

WHY DO YOU EXPERIENCE RUNNY NOSE AFTER EATING SPICY FOOD?

Spicy food – whether it’s a dash of chili in your curry, a spoonful of…

6 hours ago

“4 Simple Tests to Spot Adulterated Wheat Flour: Protect Your Health with These Easy Checks”

How To Identify Adulterated Wheat Flour? Try These 4 Easy Tests Wheat flour is a…

6 hours ago

“Unlock the Power of Jaggery: 10 Surprising Health Benefits of Eating It After Every Meal”

Reasons That Will Make You Eat Jaggery After Every Meal (Potential Health Benefits Inside) Jaggery,…

6 hours ago